

**DATE**

September 15<sup>th</sup>, 2023

**LOCATION**

Hotel NH, Trieste

Corso Camillo Benso Conte di Cavour, 7, 34132 Trieste

**SCIENTIFIC SECRETARIAT**

Dr. Marco Rabusin

**REGISTRATION**

Participation is free.

Please send your participation request by email to the Organizational Secretariat ([congressi@quickline.it](mailto:congressi@quickline.it)) indicating surname, name, tax code, profession and discipline.

**ORGANIZATIONAL SECRETARIAT**

 **QUICKLINE** Congressi

via S. Caterina da Siena, 3 - 34122 TRIESTE

Tel. 040773737 Fax 0407606590 Cell. 3357773507

e-mail: [congressi@quickline.it](mailto:congressi@quickline.it)

[www.quickline.it](http://www.quickline.it)


Provider Nazionale n. 2512

**UNDER THE PATRONAGE OF**

**AGMEN**




Friuli Venezia Giulia



# BUILDING A BRIDGE BETWEEN TRIESTE AND LJUBLJANA

## FIRST MEETING ON ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN



Trieste  
September 15<sup>th</sup>, 2023

## PROGRAM

Friday, September 15<sup>th</sup>, 2023

### 8.45 Opening and welcome

Chairman

**Dr. Marco Rabusin**

Pediatric Hemato-Oncology Unit,  
Institute of Maternal and Child Health, IRCCS Burlo Garofolo, Trieste

**Prof. Janez Jazbec**

Department of Hemato-Oncology, University Medical Center Ljubljana

### 9.00 First line treatment of ALL: the AIEOP-BFM protocol experience

**Prof. Carmelo Rizzari**

President of the European Society of Pediatric Oncology  
University of Milano-Bicocca, Pediatric Hematology Oncology Unit  
MBBM Foundation, ASST Monza

Introduced by a clinical case presented by a resident

### 9.40 Result of childhood ALL first relapse guidance

**Dr. Marko Kavcic**

Department of Hemato-Oncology, University Medical Center Ljubljana

Introduced by a clinical case presented by a resident

### 10.30 Role of flow cytometry in minimal residual disease in childhood ALL

**Prof. Veronika Koloboves, Dr. Andreja Brozic**

Department of Hemato-Oncology, University Medical Center Ljubljana

### 11.00 Coffee break

### 11.20 Role of molecular biology in diagnosis and management of ALL in pediatric patients

**Dr. Grazia Fazio**

Laboratory of Hemato-Oncology Diagnostics *M. Tettamanti*,  
Fondazione MBBM, (MB)

### 11.50 Role of HSCT in first line treatment of ALL and beyond: the AIEOP experience

**Dr. Marco Zecca**

Pediatric Hemato-Oncology Unit, IRCCS San Matteo Pavia  
Introduced by a clinical case presented by a resident

### 12.30 Peri-and post-transplant complications in slovene ALL patients

**Dr. Simona Lucija Avcin**

Department of Hemato-Oncology, University Medical Center Ljubljana

Introduced by a clinical case presented by a resident

### 13.15 Lunch

### 14.15 Immunotherapy in the management of ALL in pediatrics: is it possible to anticipate the therapeutic benefit?

**Dr. Marco Rabusin**

Pediatric Hemato-Oncology Unit, Institute of Maternal and Child Health,  
IRCCS Burlo Garofolo, Trieste

### 14.45 The burden of side effects in the management of children with ALL: the AIEOP experience

**Dr. Valentina Kiren**

Pediatric Hemato-Oncology Unit, Institute of Maternal and Child Health,  
IRCCS Burlo Garofolo, Trieste

Introduced by a clinical case presented by a resident

### 15.20 Personalisation of treatment in Acute Lymphoblastic Leukemia

**Prof. Vita Dolzan**

Institute of Pharmacology and Experimental Toxicology,  
University of Ljubljana

### 16.00 Role of pharmacogenetics and therapeutic drug monitoring in ALL treatment : the case of mercaptopurine

**Dr. Raffaella Franca**

Department of Medical, Surgical and Health Sciences,  
University of Trieste, Trieste, Italy

### 16.30 Gastrointestinal toxicity of low dose methotrexate during maintenance therapy of ALL

**Dr. Barbara Faganel Kotnik**

Department of Hemato-Oncology, University Medical Center Ljubljana

### 17.15 Closing